Indonesia Energy Corporation Limited vs Medpace Holdings Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.92 (market cap $45.55M), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 371× Indonesia Energy Corporation Limited's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | MEDP | |
|---|---|---|
Market Cap | $45.55M | $16.90B |
Sector | Energy | Technology |
52-Week High | $6.74 | $620.59 |
52-Week Low | $2.49 | $393.42 |
Enterprise Value | $40.92M | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Indonesia Energy Corporation (INDO) trades at $2.93, up 0.34% with a bullish technical signal. The stock shows negative profitability metrics including -253.4% net income margin and -26.95% ROE, though recent drilling operations at the Kruh Block indicate operational progress. Analyst consensus is unanimously bullish with 3 buy ratings. Technical indicators show bullish moving averages and neutral oscillators with RSI at 60.28.
While current fundamentals show significant losses, the company's active drilling program and 100% analyst buy rating suggest potential upside if operational execution improves. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative potential for investors comfortable with high-risk energy exploration plays.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →